Gene · 2806
Papers3,438
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,438
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Influence of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial Activity, Lipid Content, and Fatty-Acid-Binding Protein Levels in Microglial HMC3 Cells. | Pharmaceuticals (Basel) | 2023 | 38139788 | PubTator, text mining | PubMed |
| An Overview on Lipid Droplets Accumulation as Novel Target for Acute Myeloid Leukemia Therapy. | Biomedicines | 2023 | 38137407 | PubTator, text mining | PubMed |
| Age-Related Changes in Hepatic Lipid Metabolism and Abdominal Adipose Deposition in Yellow-Feathered Broilers Aged from 1 to 56 Days. | Animals (Basel) | 2023 | 38136897 | PubTator, text mining | PubMed |
| Fatty-Acid-Binding Proteins: From Lipid Transporters to Disease Biomarkers. | Biomolecules | 2023 | 38136624 | PubTator, text mining | PubMed |
| Metabolic Syndrome: A Narrative Review from the Oxidative Stress to the Management of Related Diseases. | Antioxidants (Basel) | 2023 | 38136211 | PubTator, text mining | PubMed |
| Dose Response, Dosimetric, and Metabolic Evaluations of Replacement PFAS Perfluoro-(2,5,8-trimethyl-3,6,9-trioxadodecanoic) Acid (HFPO-TeA). | Toxics | 2023 | 38133352 | PubTator, text mining | PubMed |
| Advances in research on molecular markers in immune checkpoint inhibitor-associated myocarditis. | Cancer Innov | 2023 | 38125765 | PubTator, text mining | PubMed |
| The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy. | Stem Cell Res Ther | 2023 | 38124129 | PubTator, text mining | PubMed |
| A comprehensive characterisation of phaeochromocytoma and paraganglioma tumours through histone protein profiling, DNA methylation and transcriptomic analysis genome wide. | Clin Epigenetics | 2023 | 38124114 | PubTator, text mining | PubMed |
| Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. | Cancer Res | 2023 | 38098449 | PubTator, text mining | PubMed |
| Low expression of GOT2 promotes tumor progress and predicts poor prognosis in hepatocellular carcinoma. | Biomark Med | 2023 | 38095985 | PubTator, text mining | PubMed |
| Icariin has the potential to induce the differentiation of bone marrow mesenchymal stem cells into brown fat cells via PDE5A inhibition. | Heliyon | 2023 | 38094047 | PubTator, text mining | PubMed |
| Biomarker study of symptomatic intracranial atherosclerotic stenosis in patients with acute ischemic stroke. | Front Neurol | 2023 | 38090270 | PubTator, text mining | PubMed |
| 2P-FLIM unveils time-dependent metabolic shifts during osteogenic differentiation with a key role of lactate to fuel osteogenesis via glutaminolysis identified. | Stem Cell Res Ther | 2023 | 38087380 | PubTator, text mining | PubMed |
| Prediction of post-stroke depression with combined blood biomarkers IL-6, TNF-a, and fatty acid binding protein: A prospective study. | J Med Biochem | 2023 | 38084247 | PubTator, text mining | PubMed |
| Glutamine addiction and therapeutic strategies in pancreatic cancer. | World J Gastrointest Oncol | 2023 | 38077649 | PubTator, text mining | PubMed |
| Association between "cluster of differentiation 36 (CD36)" and adipose tissue lipolysis during exercise training: a systematic review. | Front Physiol | 2023 | 38074329 | PubTator, text mining | PubMed |
| Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson's Disease-Potential Biomarkers and Therapeutic Targets. | Int J Mol Sci | 2023 | 38069360 | PubTator, text mining | PubMed |
| Meteorin-like protein elevation post-exercise improved vascular inflammation among coronary artery disease patients by downregulating NLRP3 inflammasome activity. | Aging (Albany NY) | 2023 | 38054817 | PubTator, text mining | PubMed |
| The Effects of Omega-3 Fatty Acid Supplementation on the Lipid Profile and Cardiovascular Markers Following Downhill Running in Long-Distance Runners. | J Hum Kinet | 2023 | 38053947 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2806/papers?page=10